Compare PSEC & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PSEC | CERT |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2004 | 2020 |
| Metric | PSEC | CERT |
|---|---|---|
| Price | $2.86 | $9.76 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $2.50 | ★ $12.78 |
| AVG Volume (30 Days) | ★ 4.7M | 1.8M |
| Earning Date | 02-09-2026 | 02-25-2026 |
| Dividend Yield | ★ 19.15% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $680,752,000.00 | $415,551,000.00 |
| Revenue This Year | N/A | $10.75 |
| Revenue Next Year | N/A | $6.32 |
| P/E Ratio | ★ N/A | $142.66 |
| Revenue Growth | N/A | ★ 11.47 |
| 52 Week Low | $2.45 | $8.03 |
| 52 Week High | $4.47 | $15.69 |
| Indicator | PSEC | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 60.71 | 60.99 |
| Support Level | $2.76 | $9.20 |
| Resistance Level | $3.00 | $9.85 |
| Average True Range (ATR) | 0.09 | 0.35 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 69.11 | 92.59 |
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.